FREE SHIPPING ON ORDERS OVER $150

glutathione liver phase Kanglexin, a new anthraquinone compound, attenuates hepatic fibrosis by regulating the TGF-β/SMADS signaling pathway and metabolism Frontiers | Glutathione: Pharmacological aspects

$28.28

Quantity
- +
Description

These label free quantitative experiments also confirmed the protein expression changes observed by MALDI MSI and revealed changes in key metabolic proteins, which were supported by in-situ metabolite MALDI MSI

glutathione liver phase Kanglexin, a new anthraquinone compound, attenuates hepatic fibrosis by regulating the TGF-/SMADS signaling pathway and metabolism Frontiers | Glutathione: Pharmacological aspects

It is mainly involved in regulating circadian rhythms and also possesses anti-inflammatory, antioxidant, and anti-apoptotic properties

glutathione liver phase Kanglexin, a new anthraquinone compound, attenuates hepatic fibrosis by regulating the TGF-/SMADS signaling pathway and metabolism Frontiers | Glutathione: Pharmacological aspects

doi: 10.1016/j.jalz.2013.01.005, 10 DwivediD.MeghaK.MishraR.MandalP

glutathione liver phase Kanglexin, a new anthraquinone compound, attenuates hepatic fibrosis by regulating the TGF-/SMADS signaling pathway and metabolism Frontiers | Glutathione: Pharmacological aspects

197 In breast cancer, arginine 21 (R21) and lysine 108 (K108) on mitochondrial ribosomal protein S23 (MRPS23) are methylated by methyltransferase 7 (PRMT7) and SET-domain-containing protein 6 (SETD6), respectively

glutathione liver phase Kanglexin, a new anthraquinone compound, attenuates hepatic fibrosis by regulating the TGF-/SMADS signaling pathway and metabolism Frontiers | Glutathione: Pharmacological aspects

You may also like

recommand products